1. Home
  2. JTAI vs GOVX Comparison

JTAI vs GOVX Comparison

Compare JTAI & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$0.13

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$1.68

Market Cap

4.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
GOVX
Founded
2018
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
GOVX
Price
$0.13
$1.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$11.00
$103.00
AVG Volume (30 Days)
50.9M
163.9K
Earning Date
03-26-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,584,279.00
$3,353,560.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.52
52 Week Low
$0.13
$1.63
52 Week High
$11.77
$47.13

Technical Indicators

Market Signals
Indicator
JTAI
GOVX
Relative Strength Index (RSI) 24.65 38.61
Support Level $0.13 $2.51
Resistance Level $0.17 $2.76
Average True Range (ATR) 0.04 0.26
MACD 0.03 -0.18
Stochastic Oscillator 4.45 3.93

Price Performance

Historical Comparison
JTAI
GOVX

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: